HurwitzH., FehrenbacherL., NovotnyW.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med.2004; 350(23): 2335–2342.
2.
GiantonioB.J., CatalanoP.J., MeropolN.J.; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol.2007; 25(12): 1539–1544.
3.
NalluriS.R., ChuD., KeresztesR., ZhuX., WuS.Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA.2008; 300(19): 2277–2285.
4.
HurwitzH.I., SaltzL.B., Van CutsemE.. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol.2011; 29(13): 1757–1764.
5.
HapaniS., WuS.Controversial role of bevacizumab in the development of venous thromboembolic events. J Clin Oncol.2011; 29(25): 3490.
6.
CassidyJ., ClarkeS., Díaz-RubioE.. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol.2008; 26(12): 2006–2012.
7.
BerettaG.D., PetrelliF., StincoS.. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol.2013; 30(1): 486–493.
8.
BennounaJ., SastreJ., ArnoldD.; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol.2013; 14(1): 29–37.
